Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Oliver von Richter, Terry O’Reilly, Davide Guerrieri, Jamie Fan, Constanze Fey, Steven Schussler, Fabricio Furlan & Lena Lemke. (2023) GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar. Expert Opinion on Biological Therapy 23:8, pages 749-758.
Read now
Read now
Anurag Rathore & Himanshu Malani. (2022) Need for a risk-based control strategy for managing glycosylation profile for biosimilar products. Expert Opinion on Biological Therapy 22:2, pages 123-131.
Read now
Read now
Fabrizio Cantini, Maurizio Benucci, Francesca Li Gobbi, Giulia Franchi & Laura Niccoli. (2019) Biosimilars for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology 15:11, pages 1195-1203.
Read now
Read now
Oliver von Richter, Lena Lemke, Halimuniyazi Haliduola, Alison Balfour, Britta Zehnpfennig, Andrej Skerjanec & Julia Jauch-Lembach. (2019) Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar. Expert Opinion on Biological Therapy 19:10, pages 1057-1064.
Read now
Read now
Oliver von Richter, Lena Lemke, Halimuniyazi Haliduola, Rainard Fuhr, Thomas Koernicke, Ellen Schuck, Maria Velinova, Andrej Skerjanec, Johann Poetzl & Julia Jauch-Lembach. (2019) GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods. Expert Opinion on Biological Therapy 19:10, pages 1075-1083.
Read now
Read now
Articles from other publishers (17)
Claudiu Costinel Popescu, Corina Delia Mogoșan, Luminița Enache & Cătălin Codreanu. (2022) Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort. Medicina 58:12, pages 1851.
Crossref
Crossref
Lluís Puig, Kave Shams, Fabricio Furlan, Cristofer Salvati, Elisa Romero, Jamie Fan & Lars Iversen. (2022) Real-World Effectiveness and Safety of SDZ-ADL (Adalimumab Biosimilar) in Patients with Psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). Biologics 2:4, pages 213-225.
Crossref
Crossref
Paola Karp, Matías Gatto, María Victoria Batto, Sol Ferrero & Gustavo Helguera. 2022. Biosimilars. Biosimilars.
Hui Xiong, Fengyan Luo, Pengfei Zhou & Jizu Yi. (2021) Development of a reporter gene method to measure the bioactivity of anti-CD38 × CD3 bispecific antibody. Antibody Therapeutics 4:4, pages 212-221.
Crossref
Crossref
Luisa-Fernanda Rojas-Chavarro & Fernando de Mora. (2021) Extrapolation: Experience gained from original biologics. Drug Discovery Today 26:8, pages 2003-2013.
Crossref
Crossref
Serena Patel & Meenu Wadhwa. (2021) Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. Biomedicine & Pharmacotherapy 140, pages 111785.
Crossref
Crossref
Meenu Wadhwa, Chris Bird, Eleanor Atkinson, Isabelle Cludts & Peter Rigsby. (2021) The First WHO International Standard for Adalimumab: Dual Role in Bioactivity and Therapeutic Drug Monitoring. Frontiers in Immunology 12.
Crossref
Crossref
XiaoQin Lu, Rui Hu, Lin Peng, MengSi Liu & Zhen Sun. (2021) Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis. Frontiers in Immunology 12.
Crossref
Crossref
Tom W. J. Huizinga, Yoshifumi Torii & Rafael Muniz. (2020) Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity. Rheumatology and Therapy 8:1, pages 41-61.
Crossref
Crossref
Ali M. Alsamil, Thijs J. Giezen, Toine C. Egberts, Hubert G. Leufkens & Helga Gardarsdottir. (2021) Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals 14:3, pages 189.
Crossref
Crossref
Ali M. Alsamil, Thijs J. Giezen, Toine C. Egberts, Hubert G. Leufkens & Helga Gardarsdottir. (2021) Comparison of consistency and complementarity of reporting biosimilar quality attributes between regulatory and scientific communities: An adalimumab case study. Biologicals 69, pages 30-37.
Crossref
Crossref
Ali M. Alsamil, Thijs J. Giezen, Toine C. Egberts, Hubert G. Leufkens, Arnold G. Vulto, Martijn R. van der Plas & Helga Gardarsdottir. (2020) Reporting of quality attributes in scientific publications presenting biosimilarity assessments of (intended) biosimilars: a systematic literature review. European Journal of Pharmaceutical Sciences 154, pages 105501.
Crossref
Crossref
Lan Wang, Chuanfei Yu & Junzhi Wang. (2020) Development of reporter gene assays to determine the bioactivity of biopharmaceuticals. Biotechnology Advances 39, pages 107466.
Crossref
Crossref
Ana Valido, Filipe C. Araújo, João Eurico Fonseca & João Gonçalves. (2019) A Review of Adalimumab Biosimilars for the Treatment of Immune-Mediated Rheumatic Conditions. EMJ Rheumatology, pages 122-133.
Crossref
Crossref
Obinna C. Ubah, John Steven, Andrew J. Porter & Caroline J. Barelle. (2019) An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model. Frontiers in Immunology 10.
Crossref
Crossref
D. J. Buurman, T. Blokzijl, E. A. M. Festen, B. T. Pham, K. N. Faber, E. Brouwer & G. Dijkstra. (2018) Quantitative comparison of the neutralizing capacity, immunogenicity and cross-reactivity of anti-TNF-α biologicals and an Infliximab-biosimilar. PLOS ONE 13:12, pages e0208922.
Crossref
Crossref
Young-A Heo. (2018) GP2017: An Adalimumab Biosimilar. BioDrugs 32:6, pages 635-638.
Crossref
Crossref